首页> 外文期刊>Journal of pharmacokinetics and pharmacodynamics >PK - PD of Crohn's Disease Activity Index after treatment with risankizumab, an IL-23 inhibitor

【24h】

PK - PD of Crohn's Disease Activity Index after treatment with risankizumab, an IL-23 inhibitor

机译：用IL-23抑制剂risankizumab治疗后的克罗恩病活动指数PK-PD

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of pharmacokinetics and pharmacodynamics》 |2016年第suppla期|共2页
作者
Maas Hugo; Diebold Matthias; Boecher Wulf; Lalovic Bojan;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. PK - PD of Crohn's Disease Activity Index after treatment with risankizumab, an IL-23 inhibitor [J] . Maas Hugo, Diebold Matthias, Boecher Wulf, Journal of pharmacokinetics and pharmacodynamics . 2016,第Suppla期

机译：用IL-23抑制剂risankizumab治疗后的克罗恩病活动指数PK-PD
2. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials [J] . Fan Bai, Gang Gang Li, Qingmin Liu, Journal of immunology research. . 2019,第1期

机译：IL-17，IL-12/23和IL-23抑制剂Brodalumab，Secukinumab，Ixekizumab，Ustekizumab，Guselkumab，Tildrakizumab和Risankizumab的短期疗效和安全性用于治疗中度至重度斑块牛皮癣：系统审查和随机对照试验的网络荟萃分析
3. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials [J] . Suleiman Ahmed A., Khatri Amit, Minocha Mukul, Clinical pharmacokinetics . 2019,第3期

机译：白细胞介素-33抑制剂Risankizumab的人口药代动力学在具有牛皮癣和克罗恩病的受试者中：II和II试验分析
4. Development of Combined PK/PD Studies of RAF/MEK/mTOR Inhibitors for the Treatment of Pediatric Low-Grade Astrocytomas by MALDI Mass Spectrometry Imaging [C] . David Calligaris, Xiaohui Liu, Daniel Feldman, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2013

机译：RAF / MEK / MTOR抑制剂组合PK / PD研究的研制治疗MALDI质谱成像治疗儿科低级星形细胞瘤
5. Mechanistic PK/PD Modeling of Btk Inhibitors and the Development of PET Tracers for Bacterial Infection Diagnosis [D] . Zhang, Zhuo. 2017

机译：Btk抑制剂的机理性PK / PD建模和用于细菌感染诊断的PET示踪剂的开发
6. Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn’s Disease: Results From a Randomised Phase II Biopsy Sub-study [O] . Sudha Visvanathan, Patrick Baum, Azucena Salas, -1

机译：Risankizumab对IL-23的选择性抑制作用可调节活动性克罗恩病患者结肠和回肠中的分子谱：随机II期活检亚研究的结果
7. Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn’s Disease: Results From a Randomised Phase II Biopsy Sub-study [O] . Sudha Visvanathan, Patrick Baum, Azucena Salas, 2018

机译：Risankizumab的选择性IL-23抑制调节有源CROHN疾病患者的结肠癌和回肠的分子谱：来自随机期II活检分布的结果
8. Method and Compounds for Inhibiting HEC1 Activity for the Treatment of Proliferative Diseases. [R] . Lee, W. H., Chen, P. L., Chen, Y. 2003

机译：用于抑制HEC1活性以治疗增殖性疾病的方法和化合物。

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号